Free shipping on all orders over $ 500

Zilucoplan

Cat. No. M11438

All AbMole products are for research use only, cannot be used for human consumption.

Zilucoplan Structure
Synonym:

RA101495

Size Price Availability Quantity
1mg USD 545  USD545 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Zilucoplan is a 15 amino acid macrocyclic peptide and potent complement component 5 (C5) inhibitor that specifically targets C5, a component of the terminal complement activation pathway, thereby preventing the cleavage of C5 by C5 converting enzyme into complement components C5a and C5b, and thus preventing the downstream assembly and activity of the membrane attack complex (MAC). Can be used in studies related to immune-mediated necrotizing myopathy (IMNM) and generalized myasthenia gravis (gMG).

Chemical Information
Molecular Weight 3562
Formula C172H278N24O55
CAS Number 1841136-73-9
Form Solid
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] James F Howard Jr, et al. Expert Opin Investig Drugs. Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis

[2] Declan M Gorman, et al. Amino Acids. Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan

[3] Jozefien Declercq, et al. Trials. Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial

[4] Marinos C Dalakas. Curr Opin Neurol. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies

[5] James F Howard Jr, et al. JAMA Neurol. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial

Related Complement System Products
JPE-1375

JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist. JPE-1375 effectively inhibits polymorphonuclear leukocyte mobilization (EC50=6.9 µM) and reduces TNF levels (EC50=4.5 µM) in mice.

C5aR-IN-1 

C5aR-IN-1 is a potent inhibitor of C5aR.

EG01377 dihydrochloride 

EG01377 dihydrochloride is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1), with a Kd of 1.32 μM, and IC50s of 609 nM for both NRP1-a1 and NRP1-b1.

Empasiprubart

Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation.

Avacincaptad pegol sodium

Avacincaptad pegol (ARC1905) is an anti-C5 RNA aptamer that inhibits the cleavage of complement factor 5 (C5) into C5a and C5b.

  Catalog
Abmole Inhibitor Catalog




Keywords: Zilucoplan, RA101495 supplier, Complement System, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.